The systems biology‐based argument for taking a bold step in chemoprophylaxis of sickle vasculopathy
- 17 June 2009
- journal article
- editorial
- Published by Wiley in American Journal of Hematology
- Vol. 84 (9), 543-545
- https://doi.org/10.1002/ajh.21474
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stressAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Sickle cell disease vasculopathy: A state of nitric oxide resistanceFree Radical Biology & Medicine, 2008
- Clinical trials in sickle cell disease: Adopting the combination chemotherapy paradigmAmerican Journal of Hematology, 2007
- Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypesBlood Reviews, 2007
- Protective effect of arginine on oxidative stress in transgenic sickle mouse modelsFree Radical Biology & Medicine, 2006
- The Nonlipid Effects of Statins on Endothelial FunctionTrends in Cardiovascular Medicine, 2006
- Evidence for ineffective erythropoiesis in severe sickle cell diseaseBlood, 2005
- Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatinBlood, 2004
- The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic VasculopathyMicrocirculation, 2004